Dasatinib Dose Optimization With Weekend Drug Holiday for Improved Tolerability in Chronic Myeloid Leukemia (DasaHIT): A German Chronic Myeloid Leukemia Alliance Randomized Trial
PURPOSE To compare standard-dose dasatinib 100 mg once daily with reduced-dose using a weekend drug holiday to improve tolerability for patients with chronic myeloid leukemia (CML). PATIENTS AND METHODS Patients with chronic phase CML (CP-CML) were randomly assigned to either receive standard-of-care dasatinib 100 mg once daily or an intermittent dasatinib schedule (5 days on, 2 days [weekend] off) in a prospective multicenter phase III trial. Achievement of major molecular remission (MMR) at 24 months and a newly developed cumulative toxicity score were coprimary end points. RESULTS Of 289 eligible patients, 147 were assigned to standard-of-care dasatinib and 142 to intermittent dosing. Eighty percent of patients received first-line treatment (n = 232). In the standard arm, 105 of 130 patients (81% [95% CI, 74% to 88%) achieved MMR at 24 months compared with 101 of 130 patients (78% [95% CI, 71% to 85%]) in the experimental arm resulting in noninferiority within the prespecified noninferiority margin of 15% ( P = .009). Among second- or later-line patients, MMR at 24 months was 24% lower, failing noninferiority. Comparison of grade 2-4 toxicities revealed no significant difference between the treatment arms. However, a post hoc analysis of toxicities of special interest (pleural effusion/pericardial effusion) showed 21 of 130 patients (16%) in the standard arm versus 10 of 125 (8%) patients in the experimental arm ( P = .0464). Consistently, health-related quality of life improved mainly in first-line patients, with more favorable outcomes in the experimental arm. CONCLUSION Intermittent dasatinib dosing with weekend treatment holidays in patients with CP-CML is noninferior to continuous dosing with respect to MMR at 24 months, at least in the first-line setting. The incidence of pleural or pericardial effusion appears to be reduced compared with standard-of-care continuous dosing.
Authors
- Frank Stegelmann (ORCID: https://orcid.org/0000-0003-2157-476X)
- Jenny Rinke (ORCID: https://orcid.org/0009-0006-7791-6561)
- Susanne Saußele (ORCID: https://orcid.org/0000-0003-0357-5785)
- Lino Lars Teichmann (ORCID: https://orcid.org/0000-0001-9489-7282)
- Annamaria Brioli (ORCID: https://orcid.org/0000-0002-4072-7592)
- Dominik Georg Friedrich Wolf (ORCID: https://orcid.org/0000-0002-4761-075X)
- Andreas Hochhaus (ORCID: https://orcid.org/0000-0003-0626-0834)
- Thomas Ernst (ORCID: https://orcid.org/0000-0003-2147-489X)
- Tim H. Brümmendorf (ORCID: https://orcid.org/0000-0002-9677-3723)
- Philipp Ernst (ORCID: https://orcid.org/0000-0001-5165-9874)
- Bernd Hertenstein (ORCID: https://orcid.org/0000-0001-8282-0915)
- Cornelius Florian Waller (ORCID: https://orcid.org/0000-0002-5777-0212)
- Ali Albeer (ORCID: https://orcid.org/0009-0002-1746-1260)
- Markus Pfirrmann (ORCID: https://orcid.org/0000-0002-8948-0690)
- Paul Graf La Rosée (ORCID: https://orcid.org/0000-0002-6758-7809)
- Andreas Burchert (ORCID: https://orcid.org/0000-0002-8411-8844)
- Christian Fabisch
- Ludwig Fischer von Weikersthal (ORCID: https://orcid.org/0000-0002-9128-0807)
- Theresa Früh
- on behalf of the German CML Study Group
Institutions
- Innsbruck Medical University (AT)
- University of Freiburg (DE)
- Philipps University of Marburg (DE)
- Universität Innsbruck (AT)
- Universitätsklinikum Gießen und Marburg (DE)
- University Hospital Bonn (DE)
- University Medical Center Freiburg (DE)
- Medizinische Hochschule Hannover (DE)
- Tyrolean Cancer Research Institute (AT)
- Universitätsklinikum Aachen (DE)
- Jena University Hospital (DE)
- Schwarzwald-Baar Klinikum (DE)
- Centrum für Integrierte Onkologie (DE)
- Klinikum Bremen-Mitte (DE)
- University Hospital Ulm (DE)
- University Medical Centre Mannheim (DE)
- Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1200/jco-26-00899
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00